Almenoff June Sherie — SEC insider filings

SEC reporting owner CIK 1492647. 26 insider filings on record with FilingPulse; latest filed 2026-09-04.

Transaction summary — filings shown

Covers all 26 filings on record, filed 2021-06-15 to 2026-09-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
TENAX THERAPEUTICS, INC. (TENX)Director74 legs · 3,986 sh · $29,890—5
Avalo Therapeutics, Inc. (AVTX)Director142 legs · 1,000 sh · $12,750—15
Actinium Pharmaceuticals, Inc. (ATNM)Director3——4
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)Director2——2

Insider filings — Almenoff June Sherie

FiledFormIssuerReported transactionsSource
2026-09-044Actinium Pharmaceuticals, Inc. (ATNM)Grant/award (A): 18,000 @ $0 · Grant/award (A): 27,000 (derivative) @ $0EDGAR
2026-01-134TENAX THERAPEUTICS, INC. (TENX)Grant/award (A): 30,000 (derivative) @ $0EDGAR
2025-11-204/ATENAX THERAPEUTICS, INC. (TENX)Purchase (P): 93 @ $7.15 · Purchase (P): 1,900 @ $7.52EDGAR
2025-11-194TENAX THERAPEUTICS, INC. (TENX)Purchase (P): 93 @ $7.15 · Purchase (P): 1,900 @ $7.52EDGAR
2025-07-034TENAX THERAPEUTICS, INC. (TENX)Grant/award (A): 80,000 (derivative) @ $0EDGAR
2025-06-184Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 20,100 (derivative) @ $0EDGAR
2025-04-024Actinium Pharmaceuticals, Inc. (ATNM)Disposition to issuer (D): 50,000 (derivative) @ $0EDGAR
2025-04-014Avalo Therapeutics, Inc. (AVTX)Option exercise (M): 3,167 · Option exercise (M): 3,167 (derivative) @ $0EDGAR
2024-12-124TENAX THERAPEUTICS, INC. (TENX)Grant/award (A): 100,000 (derivative) @ $0EDGAR
2024-11-144Avalo Therapeutics, Inc. (AVTX)Purchase (P): 500 @ $12.50 · Purchase (P): 500 @ $13EDGAR
2024-11-054Actinium Pharmaceuticals, Inc. (ATNM)Grant/award (A): 50,000 (derivative) @ $0EDGAR
2024-08-144Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 24,600 (derivative) @ $0 · Grant/award (A): 9,500 (derivative) @ $0EDGAR
2023-12-214Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 3,334 (derivative) @ $0EDGAR
2023-07-054Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 4,575 (derivative) @ $0EDGAR
2023-04-044Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 1,167 (derivative) @ $0EDGAR
2023-01-034Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 410 (derivative) @ $0EDGAR
2022-10-034Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 605 (derivative) @ $0EDGAR
2022-07-014Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 4,338 (derivative) @ $0EDGAR
2022-06-154Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2022-06-104TENAX THERAPEUTICS, INC. (TENX)Grant/award (A): 5,000 (derivative) @ $0EDGAR
2022-04-044Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 2,985 (derivative) @ $0EDGAR
2022-01-044Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 737 (derivative) @ $0EDGAR
2021-12-174BRAINSTORM CELL THERAPEUTICS INC. (BCLI)Grant/award (A): 2,000 @ $0EDGAR
2021-12-104BRAINSTORM CELL THERAPEUTICS INC. (BCLI)Grant/award (A): 2,000 @ $0EDGAR
2021-11-124Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 80,000 (derivative) @ $0EDGAR
2021-06-154TENAX THERAPEUTICS, INC. (TENX)Grant/award (A): 6,250 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-06-15 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1492647 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs